TY  - GEN
AU  - Ishiguro,Hiroshi
AU  - Saji,Shigehira
AU  - Nomura,Shogo
AU  - Tanaka,Sunao
AU  - Ueno,Takayuki
AU  - Onoue,Masahide
AU  - Iwata,Hiroji
AU  - Yamanaka,Takeharu
AU  - Sasaki,Yasutsuna
AU  - Toi,Masakazu
TI  - A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)
SN  - 2045-7634
PY  - 2018///0129
KW  - Adult
KW  - Aged
KW  - Antigens, CD34
KW  - blood
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Camptothecin
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Drug Combinations
KW  - Endothelial Progenitor Cells
KW  - drug effects
KW  - Female
KW  - Gene Frequency
KW  - Glucuronosyltransferase
KW  - genetics
KW  - Heterozygote
KW  - Homozygote
KW  - Humans
KW  - Irinotecan
KW  - Japan
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Oxonic Acid
KW  - Pharmacogenetics
KW  - Pharmacogenomic Variants
KW  - Phenotype
KW  - Tegafur
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1002/cam4.1258
ER  -